灰色区域和需要扩展的慢性乙型肝炎:从理论到临床实践
Thang Viet Luong1, Ngoc Phan Hong Nguyen1, Tri Van Nguyen2
1University of Medicine and Pharmacy, Hue University, Hue 530000, Viet Nam.
World journal of hepatology
|November 3, 2025
概括
在"灰色区域"的慢性乙型肝炎 (CHB) 患者面临由于治疗延迟而导致的风险. 本次审查强调,需要更新指导方针和早期干预,以便在这个脆弱群体中获得更好的结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性乙型肝炎 (CHB) 影响全球数百万人.
- 慢性心血管疾病的进展通常分为四个阶段.
- 一个重要的患者子集",灰色区域" (GZ) 无法轻松分类.
研究的目的:
- 为了应对在"灰色地带"中管理CHB患者的挑战.
- 审查当前的治疗进展和GZ患者的指导方针更新.
- 为GZ患者倡导风险适应的治疗方法.
主要方法:
- 审查关于CHB自然历史和管理的现有文献.
- 对临床指导方针和治疗策略的分析.
- 探索新的诊断和预测工具.
主要成果:
- GZ患者 (20-30%) 呈现高HBVDNA和正常ALT,具有显著的纤维化和癌症风险.
- 当前的指导方针往往忽略了GZ患者的抗病毒疗法,增加了脆弱性.
- 最近的进展为改善GZ患者管理提供了潜力.
结论:
- 在CHB护理中,GZ患者代表了关键的未满足需求.
- 新型生物标志物,非侵入性评估和人工智能模型可以帮助早期干预.
- 积极主动,风险分层的治疗方法对于改善GZ患者的治疗结果至关重要.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
468
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
468


